^Cance WG, Craven RJ, Bergman M, Xu L, Alitalo K, Liu ET (December 1994). “Rak, a novel nuclear tyrosine kinase expressed in epithelial cells”. Cell Growth Differ.5 (12): 1347–55. PMID7696183.
^Lee J, Wang Z, Luoh SM, Wood WI, Scadden DT (January 1994). “Cloning of FRK, a novel human intracellular SRC-like tyrosine kinase-encoding gene”. Gene138 (1–2): 247–51. doi:10.1016/0378-1119(94)90817-6. PMID7510261.
^Oberg-Welsh C, Welsh M (January 1995). “Cloning of BSK, a murine FRK homologue with a specific pattern of tissue distribution”. Gene152 (2): 239–42. doi:10.1016/0378-1119(94)00718-8. PMID7835707.
^Thuveson M, Albrecht D, Zürcher G, Andres AC, Ziemiecki A (April 1995). “iyk, a novel intracellular protein tyrosine kinase differentially expressed in the mouse mammary gland and intestine”. Biochem. Biophys. Res. Commun.209 (2): 582–9. doi:10.1006/bbrc.1995.1540. PMID7733928.
^Okada M, Nakagawa H (December 1989). “A protein tyrosine kinase involved in regulation of pp60c-src function”. J. Biol. Chem.264 (35): 20886–93. PMID2480346.
^ abNada S, Okada M, MacAuley A, Cooper JA, Nakagawa H (May 1991). “Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src”. Nature351 (6321): 69–72. Bibcode: 1991Natur.351...69N. doi:10.1038/351069a0. PMID1709258.
^Dehm SM, Bonham K (April 2004). “SRC gene expression in human cancer: the role of transcriptional activation”. Biochem. Cell Biol.82 (2): 263–74. doi:10.1139/o03-077. PMID15060621.
^Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE (January 2002). “Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis”. Cancer94 (2): 344–51. doi:10.1002/cncr.10221. PMID11900220.
^Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, Hennipman A, Michels AA, Staal GE (September 1992). “Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product”. Cancer Res.52 (17): 4773–8. PMID1380891.
^Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema JG, Hennipman A, Rijksen G (December 1996). “c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis”. J. Pathol.180 (4): 383–8. doi:10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N. PMID9014858.
^Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (January 1987). “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene”. Science235 (4785): 177–82. Bibcode: 1987Sci...235..177S. doi:10.1126/science.3798106. PMID3798106.
^Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (May 1989). “Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer”. Science244 (4905): 707–12. Bibcode: 1989Sci...244..707S. doi:10.1126/science.2470152. PMID2470152.
^Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R (October 2005). “Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells”. Cancer Res.65 (20): 9185–9. doi:10.1158/0008-5472.CAN-05-1731. PMID16230377.
^Chang YM, Bai L, Yang I (2002). “Survey of Src activity and Src-related growth and migration in prostate cancer lines”. Proc Am Assoc Cancer Res62: 2505a.
^Musumeci F, Schenone S, Brullo C, Botta M (April 2012). “An update on dual Src/Abl inhibitors”. Future Med Chem4 (6): 799–822. doi:10.4155/fmc.12.29. PMID22530642.